Replies to post #22713 on RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

GFP, you bring interesting angles on Org-26576. My question would be, how long could SGP keep the lid on favorable study results as proprietary info? The Cor alternative molecules and patents would certainly rise in value with any positive outcome.